Which description best matches a tumor with a high nucleus-to-cytoplasm ratio and prominent nucleoli?

Prepare for the NBME Form 16 with our comprehensive quiz. Tackle multiple choice questions with insights and explanations. Enhance your confidence and accuracy for the exam!

Multiple Choice

Which description best matches a tumor with a high nucleus-to-cytoplasm ratio and prominent nucleoli?

Explanation:
In tumor grading, a high nucleus-to-cytoplasm ratio and prominent nucleoli signal poor differentiation and aggressive behavior. When cells become less specialized, their nuclei enlarge relative to the cytoplasm, so the N:C ratio goes up. Prominent nucleoli indicate active ribosomal production and high transcriptional activity, which supports rapid cell growth. These features are hallmarks of high-grade tumors, which tend to be more invasive and have a higher likelihood of spreading compared with less differentiated forms. Benign tumors are usually well differentiated, with a lower N:C ratio, inconspicuous nucleoli, and orderly, noninvasive growth. A low- to moderate-grade tumor would show some degree of differentiation and mitotic activity but not the marked atypia seen in high-grade lesions.

In tumor grading, a high nucleus-to-cytoplasm ratio and prominent nucleoli signal poor differentiation and aggressive behavior. When cells become less specialized, their nuclei enlarge relative to the cytoplasm, so the N:C ratio goes up. Prominent nucleoli indicate active ribosomal production and high transcriptional activity, which supports rapid cell growth. These features are hallmarks of high-grade tumors, which tend to be more invasive and have a higher likelihood of spreading compared with less differentiated forms.

Benign tumors are usually well differentiated, with a lower N:C ratio, inconspicuous nucleoli, and orderly, noninvasive growth. A low- to moderate-grade tumor would show some degree of differentiation and mitotic activity but not the marked atypia seen in high-grade lesions.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy